TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28752837

Group type: EXPERIMENTAL
Intervention: UK ophthalmologists
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ANZ ophthalmologists
Number of subjects: 42

Group type: COMPARATOR
Intervention: UK group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study: 26285157

Group type: EXPERIMENTAL
Intervention: CenterVue MAIA
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nidek MP-1
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 17
Study: 25125679

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 54

Group type: COMPARATOR
Intervention: Tenofovir
Number of subjects: 54
Study: 22761551

Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Number of subjects: 0
Study: 19562243

Group type: EXPERIMENTAL
Intervention: Progressive load training for the quadriceps muscle (50% up to 80% of 1-RM) and proprioception training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drug treatment of osteoporosis (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Progressive load training and proprioception training
Number of subjects: 100
Study: 18025815

Group type: EXPERIMENTAL
Intervention: Diet alone (D, ‐2,095 +/‐ 659 kJ/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE, ‐1,420 +/‐ 1,084 kJ/day plus three 60‐min sessions per week at 60% of VO(2)max or ‐5,866 kJ/week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diet alone (D) and Diet plus exercise (DE)
Number of subjects: 20
Study: 16051927

Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes lifestyle intervention delivered by trained community residents
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (patients with diabetes in the same health care system)
Number of subjects: 151
Study: 11429352

Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with general anesthesia
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam anesthesia
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inhaled anesthesia with isoflurane
Number of subjects: 23
Study: 9605995

Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention (10-week, once weekly, 90-min/session)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard of care control condition
Number of subjects: 119
Study: 7993207

Group type: EXPERIMENTAL
Intervention: Immediate treatment with a 1 microgram/h ganciclovir implant
Number of subjects: 26

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant
Number of subjects: 26
Study: 2691815

Group type: EXPERIMENTAL
Intervention: 15 g.100 ml‐1 glucose (G)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 g.100 ml‐1 maltodextrin plus 3 g.100 ml‐1 fructose (MD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 g.100 ml‐1 sucrose (I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificially sweetened water
Number of subjects: 0
Study: 31064966

Group type: EXPERIMENTAL
Intervention: Breast milk olfactory stimulation provided 12 times over 15 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no breast milk olfactory stimulation)
Number of subjects: 28
Study: 28075422

Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program (5 days/week during RT, then 3 days/week)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care according to recommendations
Number of subjects: 72
Study: 26278231

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release (#300 mg per day) for 12-14 weeks
Number of subjects: 459
Study: 23881815

Group type: EXPERIMENTAL
Intervention: Controlled reperfusion (CR)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Per-protocol population with unilateral ischemia
Number of subjects: 174
Study: 21654269

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Febuxostat 60 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol 300 mg/d
Number of subjects: 0
Study: 19781407

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins)
Number of subjects: 1600
Study: 16721321

Group type: EXPERIMENTAL
Intervention: Paroxetine (10‐50 mg/day)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 206
Study: 15301616

Group type: EXPERIMENTAL
Intervention: Perturbed visuomotor coupling during drawing task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Figural discrepancies as additional cues
Number of subjects: 0
Study: 11775645

Group type: EXPERIMENTAL
Intervention: Essaven gel (EG) - single acute application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9623425

Group type: EXPERIMENTAL
Intervention: 0.5% S(‐)‐bupivacaine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.75% S(‐)‐bupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.5% RS‐bupivacaine
Number of subjects: 88
Study: 7919329

Group type: EXPERIMENTAL
Intervention: rhIL‐3 (2.5 or 5.0 micrograms/kg/day) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion followed by rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) until ANC > or = 1,500/microL for 3 consecutive days or until day 27 posttransplant.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) administered after rhIL‐3.
Number of subjects: 37
Study: 3260866

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 8
Study: 30054842

Group type: EXPERIMENTAL
Intervention: CEGP-003 spray
Number of subjects: 72

Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 72
Study: 26262896

Group type: EXPERIMENTAL
Intervention: 400 mg/day of algal DHA
Number of subjects: 730

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 730
Study: 24172538

Group type: EXPERIMENTAL
Intervention: Noisy pressure support ventilation (PSV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional pressure support ventilation (PSV)
Number of subjects: 13
Study: 21178599

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (nonhypnotic relaxation)
Number of subjects: 39
Study: 18311747

Group type: EXPERIMENTAL
Intervention: Aurora kinase B expression
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Genomic instability related to Aurora kinase B expression
Number of subjects: 107
Study: 16546105

Group type: EXPERIMENTAL
Intervention: MMC, 0.2 mg/ml applied for three minutes (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conjunctival autografting alone (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% only (Group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conjunctival autografting combined with one minute application of MMC, 0.2 mg/ml (Group 4)
Number of subjects: 120
Study: 12403254

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10660096

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg/day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8570427

Group type: EXPERIMENTAL
Intervention: Canola oil cookies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coconut oil cookies
Number of subjects: 0
Study: 2179650

Group type: EXPERIMENTAL
Intervention: Feedback to physicians of SDS scores of previously unrecognized depressed patients
Number of subjects: 100
Study: 380253

Group type: EXPERIMENTAL
Intervention: Paracetamol (0.5 g x 4 for 3 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (0.5 g x 4 for 3 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Number of subjects: 30
Study: 6578865

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study: 30829734

Group type: EXPERIMENTAL
Intervention: Continuous preperitoneal wound infiltration (PPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural analgesia (EDB)
Number of subjects: 40
Study: 30404139

Group type: EXPERIMENTAL
Intervention: Random Forest model using NDVI series from the 120th to the 210th day in a year with 10 days' interval as predictors for maize yield estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random Forest model using a combination of three NDVI characteristics, three phenological characteristics, and two curve parameters as predictors for sunflower yield estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NDVI series 50 days before crop harvest for both maize and sunflower
Number of subjects: 0
Study: 27067129

Group type: EXPERIMENTAL
Intervention: Patients with psychosis (younger and older)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Younger patients with psychosis
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Older patients with psychosis
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Female patients with psychosis
Number of subjects: 224
Study: 25124683

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bupropion XL
Number of subjects: 41
Study: 22238353

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR treatment for 48 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inactive group after treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model of assessment‐insulin resistance
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone (GH)
Number of subjects: 27
Study: 20846991

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001

Group type: EXPERIMENTAL
Intervention: Low BP (<110‐120/<60‐70 mmHg)
Number of subjects: 10001
Study: 18094424

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g daily for 3 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5% glucose (control)
Number of subjects: 120
Study: 15951310

Group type: EXPERIMENTAL
Intervention: 4% dimeticone lotion (applied for eight hours or overnight)
Number of subjects: 253

Group type: COMPARATOR
Intervention: 0.5% phenothrin liquid (applied for 12 hours or overnight)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: 4% dimeticone lotion
Number of subjects: 253

Group type: COMPARATOR
Intervention: 0.5% phenothrin liquid
Number of subjects: 253
Study: 12401583

Group type: EXPERIMENTAL
Intervention: Isovolemic Hemodilution (IVH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypervolemic Hemodilution (HVH)
Number of subjects: 30
Study: 10449124

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor (ARI) zenarestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8714853

Group type: EXPERIMENTAL
Intervention: EMLA cream applied 60 min prior to local anesthesia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no EMLA cream)
Number of subjects: 33
Study: 2220573

Group type: EXPERIMENTAL
Intervention: In-field ECG (n = 34)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No ECG (n = 37)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No ECG (n = 6 concurrent control patients)
Number of subjects: 71
Study: 393076

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 g/kg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Alcohol 1.2 g/kg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Diazepam 2 mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Alcohol with diazepam
Number of subjects: 218
Study: 31782023

Group type: EXPERIMENTAL
Intervention: PBMT/sMF with 30 J per site
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham (0 J)
Number of subjects: 10
Study: 30906300

Group type: EXPERIMENTAL
Intervention: DQB1*02:01
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: DQB1*02:02
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: DRB1*01:01, DRB1*04:05, DRB1*09:01, DRB1*12:02, DRB1*13:02, DRB1*14:01
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: DPB1*05:01
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: DPB1*04:01, DPB1*09:01
Number of subjects: 373
Study: 29727535

Group type: EXPERIMENTAL
Intervention: Pancreatic kininogenase (120 u, tid) and sildenafil (25 mg, qd at bedtime)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sildenafil (25 mg, qd at bedtime)
Number of subjects: 93
Study: 25458076

Group type: EXPERIMENTAL
Intervention: Senofilcon‐A soft lenses of -6.00 D
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Senofilcon‐A soft lenses of -3.00 D
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Senofilcon‐A soft lenses of +3.00 D
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Senofilcon‐A soft lenses of +6.00 D
Number of subjects: 16

Group type: COMPARATOR
Intervention: Positive soft lens powers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Negative soft lens powers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All soft lens powers
Number of subjects: 16
Study: 23335263

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (dietary sodium reduction, lycopene, omega-3 fatty acids)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 21087222

Group type: EXPERIMENTAL
Intervention: Individualized nutritional treatment from a dietitian in the hospital and three home visits after discharge
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (combined Group 2 and Group 3)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Individualized nutritional treatment
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study: 19297636

Group type: EXPERIMENTAL
Intervention: Moderate levels of manipulated expert witness confidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juror extroversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert witness credibility ratings
Number of subjects: 0
Study: 17885542

Group type: EXPERIMENTAL
Intervention: Reduced-sodium, high-potassium salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulphate)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Normal salt (100% sodium chloride)
Number of subjects: 608
Study: 15491311

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 dentifrice and mouthrinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaF-containing dentifrice and mouthrinse
Number of subjects: 80
Study: 12050092

Group type: EXPERIMENTAL
Intervention: Biomarker Feedback (BF)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 557
Study: 9697784

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia using bupivacaine combined with light general anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General endotracheal anesthesia with postoperative intravenous morphine patient-controlled analgesia
Number of subjects: 40
Study: 7875666

Group type: EXPERIMENTAL
Intervention: High dose cefotaxime (2 g every 6 hours)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Low dose cefotaxime (2 g every 12 hours)
Number of subjects: 143
Study: 2087437

Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptamine (2 nmol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bradykinin (2 nmol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixture of 5-Hydroxytryptamine and Bradykinin (1 nmol + 1 nmol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (0.2 ml)
Number of subjects: 19
Study: 35195

Group type: EXPERIMENTAL
Intervention: Clobazam 15 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clobazam 30 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30380053

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Control group (ART initiators)
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Control group (established ART patients)
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Dolutegravir with a cytosine analogue plus tenofovir or abacavir
Number of subjects: 1287
Study: 25575616

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal delivery system (MTS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo transdermal system (PTS)
Number of subjects: 0
Study: 26979588

Group type: EXPERIMENTAL
Intervention: Healthy=green, unhealthy=red (HGUR)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Healthy=red, unhealthy=green (HRUG)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No colour (control)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Unhealthy foods with different colouring schemes
Number of subjects: 196
Study: 24275085

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Music training
Number of subjects: 76

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 76
Study: 23631266

Group type: EXPERIMENTAL
Intervention: Regular consumption of school lunches
Number of subjects: 380

Group type: COMPARATOR
Intervention: No consumption of school lunches
Number of subjects: 380
Study: 19858915

Group type: EXPERIMENTAL
Intervention: Group culture
Number of subjects: 18361

Group type: EXPERIMENTAL
Intervention: Hierarchical culture
Number of subjects: 18361

Group type: COMPARATOR
Intervention: Organizational culture
Number of subjects: 18361

Group type: EXPERIMENTAL
Intervention: Mix of culture types emphasizing group culture
Number of subjects: 18361
Study: 17846102

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 103
Study: 15172084

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CEE + medroxyprogesterone acetate (CEE/MPA) 5 mg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 84
Study: 11800516

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-I treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9591509

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of estradiol and progesterone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7882660

Group type: EXPERIMENTAL
Intervention: Continuing education intervention 'Periodontics in General Practice' including a 1-day seminar, bi-monthly newsletters, individualized 3-monthly comparative feedback, and technical assistance.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuing education intervention 'Periodontics in General Practice' for practices employing hygienists.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 36
Study: 3255811

Group type: EXPERIMENTAL
Intervention: Combination therapy (liquid nitrogen + wart paint)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Liquid nitrogen applied weekly
Number of subjects: 3

Group type: COMPARATOR
Intervention: Daily application of wart paint (lactic acid one part, salicylic acid one part, collodion four parts)
Number of subjects: 3
Study: 29525239

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 64
Study: 26640973

Group type: EXPERIMENTAL
Intervention: Standardized patient (SP)‐based intervention with feedback on patient-centered techniques
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standardized patient (SP)‐based intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (SP visits without feedback)
Number of subjects: 61
Study: 23666379

Group type: EXPERIMENTAL
Intervention: Focused Shockwave Therapy (FSWT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Radial Shockwave Therapy (RSWT)
Number of subjects: 43
Study: 23536950

Group type: EXPERIMENTAL
Intervention: Succinate-containing dialysis solution (SCDS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis solution
Number of subjects: 90
Study: 20510838

Group type: EXPERIMENTAL
Intervention: Programmed distraction during venipuncture (looking at two similar pictures and identifying differences)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (pretest sessions)
Number of subjects: 42
Study: 19453400

Group type: EXPERIMENTAL
Intervention: Inactivated, aluminium‐adjuvanted, whole‐virion prototype pandemic influenza A (H5N1) vaccine (PanFlu)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma from a vaccinated individual
Number of subjects: 0